Home > Drug Search >
  • Targets: Calcium-activated potassium channel (Gardos channel)
  •   > 
Drug Filter
Status:
Approved (6) Phase Ⅲ (4) Phase Ⅱ (5) Phase Ⅰ (14) IND Filing (1)
Clinical Stage:
Pending (2) Active (17) Discontinued (5)
Company:
Exelixis (2) Hansoh Pharma (1) Johnson & Johnson (1) Novartis (1) Pfizer (3) Rottapharm (1) Sanofi (1) Tesaro (1) Teva (1) Stason pharma (1) Alexar Therapeutics (1) Fochon Pharmaceuticals (1) Ignyta Pharma (1) Nerviano Medical Sciences (1) Zai Lab (1) Centaurus Biopharma (1) Beijing Pearl Biotechnology (1) Hikma (1) Xcovery (1) Shanghai Institute of Materia Medica, Chinese Academy of Sciences (1) Vitae (1) Southeast University (1) TP Therapeutics (1) Icagen (1) Akron Molecules (1) University of Cambridge (1) Eternity Bioscience (1) Amgen (1) Ariad (1) Astellas (1) Betta (1) Boehringer Ingelheim (1) Bristol-Myers Squibb (2) Chiatai Tianqing (CTTQ) (1) Chugai (1)
Indication:
Acute lymphoblastic leukaemia (ALL) (1) Allergic rhinitis (AR) (1) Asthma (1) Atherosclerosis (3) Atopic dermatitis (2) Apnoea (1) Chronic obstructive pulmonary disease (COPD) (1) Anaplastic lymphoma kinase (ALK)-positive NSCLC (3) ROS1-positive non-small cell lung cancer(NSCLC) (1) Epilepsy/Seizures (1) Gastric cancer (1) Hypercholesterolemia (1) Lung cancer (1) Lymphoma (2) Non small cell lung cancer (NSCLC) (13) Parkinson's disease (PD) (1) Pulmonary arterial hypertension (1) Solid tumours (4) Colorectal cancer (1) Pain (2) Metastatic non-small cell lung cancer (1) B-cell lymphoma (1) Sickle cell disease (1) Central nervous system tumors (1)
Country:
Aprv. Year:
1999 (1) 2011 (1) 2014 (2) 2017 (1)
Others:
Sort: Aprv. Year Alphabetical Prev Next
First Prev 1 2 Next Last GO
Recently Viewed Drugs:
Insert title here
Feed-Back To Top
ICP Permit 14047345| Beijing PSB Hai Dian Record 11010802017043 |(京)-经营性-2015-0023(互联网药品信息服务资格证书)
Insert title here
Feed-Back To Top